Stockscreener 앱 받기
39.86
28.77%
-17.49
전일 마감가:
$57.35
열려 있는:
$44.02
하루 거래량:
10.64M
Relative Volume:
9.58
시가총액:
$3.86B
수익:
$7.50M
순이익/손실:
$-383.17M
주가수익비율:
-8.4727
EPS:
-4.7048
순현금흐름:
$-307.84M
1주 성능:
-30.35%
1개월 성능:
-35.34%
6개월 성능:
-25.82%
1년 성능:
+8.18%
1일 변동 폭
$39.70
$44.85
1주일 범위
$39.83
$59.60
52주 변동 폭
$35.97
$72.66
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
39.84 | 5.68B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
505.85 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.53 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
995.24 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
155.00 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
189.10 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Xenon Pharmaceuticals: Epilepsy Got It To $59; Depression Has To Take It From Here - Seeking Alpha
Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care - Yahoo Finance
A drugmaker plans a 30-minute healthcare talk in Boston Sept. 9. Xenon will present. - Stock Titan
Behavioral Patterns of XENE and Institutional Flows - Stock Traders Daily
Xenon to Present at Wells Fargo Healthcare Conference - Yahoo Finance
Xenon Pharmaceuticals stock holds firm as analysts stick to buy ratings - ad-hoc-news.de
Xenon Pharmaceuticals (XENE) CMO sells 7,068 shares in Rule 10b5-1 plan trades around $61. - Stock Titan
Xenon Pharma (NASDAQ: XENE) holder to sell 7,068 shares - Stock Titan
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com
Xenon Pharmaceuticals to present epilepsy drug data at congress - Investing.com India
Xenon Pharmaceuticals Announces Multiple Data Presentations for Azetukalner At Eec 2026 - marketscreener.com
A Phase 3 epilepsy study is among Xenon's six planned Europe presentations - Stock Titan
Bank of America Corp DE Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon (XENE) Today: Ends Down by 4.16% at $59.73 for the Current Session; Technical Setup: Support at $56.74 and Resistance at $62.72 Frame the Range under the Current SnapshotMcClellan Oscillator - Vinanet
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript - AOL.com
Xenon (XENE) Range: Moves 1.36% Down to $62.32 for the Current Session; Price Levels - vinanet.vn
Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors? - simplywall.st
Xenon Pharmaceuticals (XENE) Holds Steady at $62.36 as Shares Consolidate Below Key ResistanceIV Rank - vinanet.vn
TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) Could Be 23% Undervalued As Epilepsy Growth Narrative Holds - Sahm
Xenon Pharmaceuticals (XENE) Pulls Back 2.93% as Shares Approach Critical SupportCall Wall - vinanet.vn
XENE Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Shares Dip 2.93%Energy Earnings Report - vinanet.vn
Xenon Pharmaceuticals Independent Director Steven Gannon Sells 84% Of Holding - simplywall.st
Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals (XENE) Insider Sells 10,000 Shares; Direct - GuruFocus
(XENE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) Director Sells 10,000 Shares of Stock - MarketBeat
Xenon Pharmaceuticals (XENE) director sells 10,000 common shares at $64 - Stock Titan
Xenon Pharmaceuticals Insider Sold Shares Worth $640,550, According to a Recent SEC Filing - marketscreener.com
Xenon Pharmaceuticals Director Sold Shares Worth Over $640K - TradingView
Seller for XENE (NASDAQ: XENE) plans 10,000-share common stock sale - Stock Titan
Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Presents High-Quality Technical Breakout Setup - ChartMill
Xenon Pharmaceuticals (XENE) Jumps 3.23% to $65.26: Key Levels to WatchETF Creation Redemption - vinanet.vn
Xenon Pharmaceuticals Director Steven Gannon Sells 10,000 Shares at $64.06 Average Price - Kalkine Media
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity (XENE) - Seeking Alpha
HC Wainwright Issues Positive Outlook for XENE Earnings - MarketBeat
Xenon Pharmaceuticals Inc. (XENE): Analyst Consensus Highlights 26.65% Potential Upside - DirectorsTalk Interviews
Xenon Pharmaceuticals (XENE) Edges Lower to $63.81 as Shares Consolidate Between Support and ResistancePut Spread Alert - vinanet.vn
H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy - Investing.com
H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Brokers Issue Forecasts for XENE Q1 Earnings - MarketBeat
Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
FDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals (XENE) - webull.com
Xenon Pharmaceuticals Stock Price Forecast. Should You Buy XENE? - StockInvest.us
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $81 to $90 - Moomoo
H.C. Wainwright Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $74 - Moomoo
XENE Maintained by RBC Capital -- Price Target Lowered to $81.00 - GuruFocus
Xenon Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xenon Pharmaceuticals Inc 주식 (XENE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer |
Aug 28 '26 |
Sale |
60.25 |
7,068 |
425,829 |
2 |
1.15%
0.73%
자본화:
|
볼륨(24시간):